25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ICY (Incyte) Stock Analysis
Buy, Hold or Sell?

Let's analyze Incyte together

I guess you are interested in Incyte Corporation. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Incyte’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Incyte’s Price Targets

I'm going to help you getting a better view of Incyte Corporation. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Incyte Corporation

I send you an email if I find something interesting about Incyte Corporation.

1. Quick Overview

1.1. Quick analysis of Incyte (30 sec.)










1.2. What can you expect buying and holding a share of Incyte? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€18.21
Expected worth in 1 year
€23.34
How sure are you?
85.7%

+ What do you gain per year?

Total Gains per Share
€5.13
Return On Investment
7.0%

For what price can you sell your share?

Current Price per Share
€73.38
Expected price per share
€61.30 - €78.52
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Incyte (5 min.)




Live pricePrice per Share (EOD)
€73.38
Intrinsic Value Per Share
€-9.07 - €-11.79
Total Value Per Share
€9.15 - €6.42

2.2. Growth of Incyte (5 min.)




Is Incyte growing?

Current yearPrevious yearGrowGrow %
How rich?$4.1b$4.6b-$1b-28.1%

How much money is Incyte making?

Current yearPrevious yearGrowGrow %
Making money$217.7m$24.3m$193.4m88.8%
Net Profit Margin18.7%3.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Incyte (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#25 / 857

Most Revenue
#14 / 857

Most Profit
#18 / 857
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Incyte?

Welcome investor! Incyte's management wants to use your money to grow the business. In return you get a share of Incyte.

First you should know what it really means to hold a share of Incyte. And how you can make/lose money.

Speculation

The Price per Share of Incyte is €73.38. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Incyte.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Incyte, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €18.21. Based on the TTM, the Book Value Change Per Share is €1.28 per quarter. Based on the YOY, the Book Value Change Per Share is €-1.25 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Incyte.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 β‚¬% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share
Usd Eps2.072.8%1.121.5%0.030.0%0.520.7%0.630.9%0.330.5%
Usd Book Value Change Per Share2.583.5%1.502.0%-1.47-2.0%0.240.3%0.530.7%0.610.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share2.583.5%1.502.0%-1.47-2.0%0.240.3%0.530.7%0.610.8%
Usd Price Per Share68.38-70.00-65.00-70.92-74.93-83.14-
Price to Earnings Ratio8.24-19.69-13.19-46.31-23.52-29.74-
Price-to-Total Gains Ratio26.53-54.10-50.92-79.84-110.14-38.40-
Price to Book Ratio3.20-3.83-3.19-3.64-4.50-9.51-
Price-to-Total Gains Ratio26.53-54.10-50.92-79.84-110.14-38.40-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share86.067402
Number of shares11
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share1.500.53
Usd Total Gains Per Share1.500.53
Gains per Quarter (11 shares)16.535.83
Gains per Year (11 shares)66.1323.34
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10665602313
2013212204736
3019818807059
4026525409382
503313200117105
603973860140128
704634520163151
805295180187174
905955840210197
1006616500233220

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%11.01.00.091.7%18.02.00.090.0%28.07.00.080.0%28.07.00.080.0%
Book Value Change Per Share4.00.00.0100.0%11.01.00.091.7%19.01.00.095.0%30.05.00.085.7%30.05.00.085.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.035.00.0%0.00.035.00.0%
Total Gains per Share4.00.00.0100.0%11.01.00.091.7%19.01.00.095.0%30.05.00.085.7%30.05.00.085.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Incyte Corporation compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--2.1981.281+72%-1.253+157%0.207+960%0.452+386%0.520+322%
Book Value Per Share--18.21315.782+15%18.017+1%16.944+7%15.101+21%11.362+60%
Current Ratio--2.8502.183+31%3.263-13%3.073-7%3.364-15%3.705-23%
Debt To Asset Ratio--0.2840.345-18%0.266+7%0.283+0%0.270+5%0.289-2%
Debt To Equity Ratio--0.3960.531-25%0.370+7%0.404-2%0.376+5%0.460-14%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--9977259685.80010040311262.425-1%10639442889.770-6%11419622933.985-13%12577938734.434-21%14938112683.521-33%
Eps--1.7680.951+86%0.030+5864%0.444+299%0.538+229%0.282+527%
Ev To Sales Ratio--2.4072.568-6%3.253-26%3.462-30%4.352-45%7.617-68%
Free Cash Flow Per Share--0.1121.032-89%-0.222+298%0.493-77%0.511-78%0.376-70%
Free Cash Flow To Equity Per Share--0.0630.993-94%-2.449+3989%-0.263+517%0.065-3%-0.020+131%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---11.791----------
Intrinsic Value_10Y_min---9.066----------
Intrinsic Value_1Y_max--1.517----------
Intrinsic Value_1Y_min--1.492----------
Intrinsic Value_3Y_max--2.502----------
Intrinsic Value_3Y_min--2.430----------
Intrinsic Value_5Y_max--1.007----------
Intrinsic Value_5Y_min--1.111----------
Market Cap14329363520.100+21%11384599253.50011654080333.600-2%12015517359.270-5%12811112158.793-11%13771275202.529-17%15893194813.298-28%
Net Profit Margin--0.3330.187+78%0.038+781%0.109+206%0.144+132%0.066+405%
Operating Margin----0%-0%0.024-100%0.088-100%0.047-100%
Operating Ratio--0.8090.856-5%1.045-23%0.948-15%0.916-12%1.056-23%
Pb Ratio4.029+21%3.2013.826-16%3.189+0%3.642-12%4.504-29%9.508-66%
Pe Ratio10.373+21%8.24219.688-58%13.188-38%46.314-82%23.520-65%29.738-72%
Price Per Share73.380+21%58.30059.680-2%55.420+5%60.463-4%63.881-9%70.882-18%
Price To Free Cash Flow Ratio163.680+21%130.04341.006+217%15.867+720%20.260+542%27.669+370%16.383+694%
Price To Total Gains Ratio33.386+21%26.52554.101-51%50.916-48%79.840-67%110.137-76%38.399-31%
Quick Ratio--1.0240.850+21%0.911+12%0.874+17%0.952+8%1.097-7%
Return On Assets--0.0700.039+79%-0.004+105%0.017+313%0.024+185%0.010+627%
Return On Equity--0.0970.058+67%-0.011+111%0.022+332%0.032+200%0.011+766%
Total Gains Per Share--2.1981.281+72%-1.253+157%0.207+960%0.452+386%0.520+322%
Usd Book Value--4171452850.1423614804976.926+15%4628763629.476-10%4231387583.630-1%3815630848.311+9%2938359369.999+42%
Usd Book Value Change Per Share--2.5781.503+72%-1.470+157%0.243+960%0.530+386%0.610+322%
Usd Book Value Per Share--21.36218.511+15%21.132+1%19.874+7%17.712+21%13.326+60%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--11702327885.47511776281079.698-1%12479002565.411-6%13394075739.271-13%14752664341.618-21%17520912366.502-33%
Usd Eps--2.0741.115+86%0.035+5864%0.520+299%0.631+229%0.331+527%
Usd Free Cash Flow--25670383.681236426914.052-89%-34885348.329+236%125324769.387-80%130942859.922-80%60618047.367-58%
Usd Free Cash Flow Per Share--0.1311.211-89%-0.260+298%0.578-77%0.600-78%0.441-70%
Usd Free Cash Flow To Equity Per Share--0.0741.165-94%-2.872+3989%-0.308+517%0.076-3%-0.023+131%
Usd Market Cap16806910472.725+21%13352996464.43013669070823.279-2%14093000310.688-5%15026153451.049-11%16152328685.046-17%18641128196.517-28%
Usd Price Per Share86.067+21%68.38069.999-2%65.002+5%70.916-4%74.926-9%83.137-18%
Usd Profit--405052391.018217746201.698+86%24326956.600+1565%111235662.264+264%130882451.959+209%69697472.721+481%
Usd Revenue--1215689243.1881146400110.006+6%964380617.539+26%996406005.556+22%899935972.921+35%718844838.538+69%
Usd Total Gains Per Share--2.5781.503+72%-1.470+157%0.243+960%0.530+386%0.610+322%
 EOD+4 -4MRQTTM+22 -13YOY+22 -133Y+21 -155Y+19 -1710Y+22 -14

3.3 Fundamental Score

Let's check the fundamental score of Incyte Corporation based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1510.373
Price to Book Ratio (EOD)Between0-14.029
Net Profit Margin (MRQ)Greater than00.333
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.024
Current Ratio (MRQ)Greater than12.850
Debt to Asset Ratio (MRQ)Less than10.284
Debt to Equity Ratio (MRQ)Less than10.396
Return on Equity (MRQ)Greater than0.150.097
Return on Assets (MRQ)Greater than0.050.070
Total7/10 (70.0%)

3.4 Technical Score

Let's check the technical score of Incyte Corporation based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5056.652
Ma 20Greater thanMa 5072.063
Ma 50Greater thanMa 10070.959
Ma 100Greater thanMa 20064.718
OpenGreater thanClose73.380
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Incyte Corporation

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Fundamental data was last updated by Penke on 2025-09-21 17:52:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is fair priced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Incyte earns for each €1 of revenue.

  • Above 10% is considered healthy but always compareΒ Incyte to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 33.3%Β means thatΒ €0.33 for each €1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Incyte Corporation:

  • The MRQ is 33.3%. The company is making a huge profit. +2
  • The TTM is 18.7%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ33.3%TTM18.7%+14.6%
TTM18.7%YOY3.8%+14.9%
TTM18.7%5Y14.4%+4.3%
5Y14.4%10Y6.6%+7.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ33.3%-65.5%+98.8%
TTM18.7%-147.4%+166.1%
YOY3.8%-189.7%+193.5%
3Y10.9%-259.0%+269.9%
5Y14.4%-337.1%+351.5%
10Y6.6%-472.3%+478.9%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Incyte is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Incyte to theΒ Biotechnology industry mean.
  • 7.0% Return on Assets means thatΒ Incyte generatedΒ €0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Incyte Corporation:

  • The MRQ is 7.0%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 3.9%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ7.0%TTM3.9%+3.1%
TTM3.9%YOY-0.4%+4.3%
TTM3.9%5Y2.4%+1.4%
5Y2.4%10Y1.0%+1.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.0%-11.9%+18.9%
TTM3.9%-11.9%+15.8%
YOY-0.4%-11.3%+10.9%
3Y1.7%-12.0%+13.7%
5Y2.4%-11.9%+14.3%
10Y1.0%-14.0%+15.0%
4.3.1.3. Return on Equity

Shows how efficient Incyte is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Incyte to theΒ Biotechnology industry mean.
  • 9.7% Return on Equity means Incyte generated €0.10Β for eachΒ €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Incyte Corporation:

  • The MRQ is 9.7%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 5.8%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ9.7%TTM5.8%+3.9%
TTM5.8%YOY-1.1%+6.9%
TTM5.8%5Y3.2%+2.6%
5Y3.2%10Y1.1%+2.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.7%-14.1%+23.8%
TTM5.8%-14.7%+20.5%
YOY-1.1%-15.3%+14.2%
3Y2.2%-16.8%+19.0%
5Y3.2%-17.4%+20.6%
10Y1.1%-19.8%+20.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Incyte Corporation.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Incyte is operatingΒ .

  • Measures how much profit Incyte makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Incyte to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated €0.00 Β for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Incyte Corporation:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y8.8%-8.8%
5Y8.8%10Y4.7%+4.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--148.3%+148.3%
TTM--255.8%+255.8%
YOY--240.0%+240.0%
3Y2.4%-245.6%+248.0%
5Y8.8%-330.8%+339.6%
10Y4.7%-487.4%+492.1%
4.3.2.2. Operating Ratio

Measures how efficient Incyte is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.81 means that the operating costs are €0.81 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Incyte Corporation:

  • The MRQ is 0.809. The company is less efficient in keeping operating costs low.
  • The TTM is 0.856. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.809TTM0.856-0.046
TTM0.856YOY1.045-0.189
TTM0.8565Y0.916-0.060
5Y0.91610Y1.056-0.140
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8091.853-1.044
TTM0.8562.652-1.796
YOY1.0452.829-1.784
3Y0.9483.550-2.602
5Y0.9164.636-3.720
10Y1.0566.253-5.197
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Incyte Corporation.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Incyte is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 2.85Β means the company has €2.85 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Incyte Corporation:

  • The MRQ is 2.850. The company is able to pay all its short-term debts. +1
  • The TTM is 2.183. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.850TTM2.183+0.667
TTM2.183YOY3.263-1.080
TTM2.1835Y3.364-1.181
5Y3.36410Y3.705-0.341
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8503.448-0.598
TTM2.1833.644-1.461
YOY3.2634.060-0.797
3Y3.0734.461-1.388
5Y3.3645.731-2.367
10Y3.7056.128-2.423
4.4.3.2. Quick Ratio

Measures if Incyte is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Incyte to theΒ Biotechnology industry mean.
  • A Quick Ratio of 1.02Β means the company can pay off €1.02 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Incyte Corporation:

  • The MRQ is 1.024. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 0.850. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ1.024TTM0.850+0.175
TTM0.850YOY0.911-0.061
TTM0.8505Y0.952-0.102
5Y0.95210Y1.097-0.145
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0242.764-1.740
TTM0.8503.124-2.274
YOY0.9113.845-2.934
3Y0.8744.322-3.448
5Y0.9525.680-4.728
10Y1.0976.522-5.425
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Incyte Corporation.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of IncyteΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Incyte to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.28Β means that Incyte assets areΒ financed with 28.4% credit (debt) and the remaining percentage (100% - 28.4%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Incyte Corporation:

  • The MRQ is 0.284. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.345. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.284TTM0.345-0.061
TTM0.345YOY0.266+0.079
TTM0.3455Y0.270+0.075
5Y0.27010Y0.289-0.020
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2840.341-0.057
TTM0.3450.361-0.016
YOY0.2660.331-0.065
3Y0.2830.343-0.060
5Y0.2700.350-0.080
10Y0.2890.381-0.092
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Incyte is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Incyte to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 39.6% means that company has €0.40 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Incyte Corporation:

  • The MRQ is 0.396. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.531. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.396TTM0.531-0.135
TTM0.531YOY0.370+0.161
TTM0.5315Y0.376+0.155
5Y0.37610Y0.460-0.084
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3960.395+0.001
TTM0.5310.438+0.093
YOY0.3700.432-0.062
3Y0.4040.471-0.067
5Y0.3760.467-0.091
10Y0.4600.518-0.058
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every €1 in earnings Incyte generates.

  • Above 15 is considered overpriced butΒ always compareΒ Incyte to theΒ Biotechnology industry mean.
  • A PE ratio of 8.24 means the investor is paying €8.24Β for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Incyte Corporation:

  • The EOD is 10.373. Based on the earnings, the company is underpriced. +1
  • The MRQ is 8.242. Based on the earnings, the company is underpriced. +1
  • The TTM is 19.688. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD10.373MRQ8.242+2.132
MRQ8.242TTM19.688-11.446
TTM19.688YOY13.188+6.500
TTM19.6885Y23.520-3.832
5Y23.52010Y29.738-6.218
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD10.373-2.738+13.111
MRQ8.242-2.296+10.538
TTM19.688-2.657+22.345
YOY13.188-3.631+16.819
3Y46.314-3.737+50.051
5Y23.520-5.974+29.494
10Y29.738-6.848+36.586
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Incyte Corporation:

  • The EOD is 163.680. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 130.043. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 41.006. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD163.680MRQ130.043+33.637
MRQ130.043TTM41.006+89.037
TTM41.006YOY15.867+25.138
TTM41.0065Y27.669+13.337
5Y27.66910Y16.383+11.286
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD163.680-3.422+167.102
MRQ130.043-2.906+132.949
TTM41.006-3.631+44.637
YOY15.867-4.296+20.163
3Y20.260-5.238+25.498
5Y27.669-8.367+36.036
10Y16.383-9.706+26.089
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Incyte is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 3.20 means the investor is paying €3.20Β for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Incyte Corporation:

  • The EOD is 4.029. Based on the equity, the company is fair priced.
  • The MRQ is 3.201. Based on the equity, the company is fair priced.
  • The TTM is 3.826. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD4.029MRQ3.201+0.828
MRQ3.201TTM3.826-0.625
TTM3.826YOY3.189+0.637
TTM3.8265Y4.504-0.678
5Y4.50410Y9.508-5.004
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.0292.488+1.541
MRQ3.2012.047+1.154
TTM3.8262.204+1.622
YOY3.1892.464+0.725
3Y3.6422.632+1.010
5Y4.5043.755+0.749
10Y9.5084.450+5.058
4.6.2. Total Gains per Share

2.4. Latest News of Incyte Corporation

Does Incyte Corporation still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Incyte Corporation to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-09-27
06:59
Incyte (INCY) Advances Clinical Trials for Povorcitinib Across Multiple ConditionsRead
2025-09-20
14:27
How Investors May Respond To Incyte (INCY) Expanding Opzelura’s Pediatric Use Following FDA ApprovalRead
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets5,821,354
Total Liabilities1,650,451
Total Stockholder Equity4,170,903
 As reported
Total Liabilities 1,650,451
Total Stockholder Equity+ 4,170,903
Total Assets = 5,821,354

Assets

Total Assets5,821,354
Total Current Assets3,643,701
Long-term Assets2,177,653
Total Current Assets
Cash And Cash Equivalents 1,954,969
Short-term Investments 466,769
Net Receivables 842,892
Inventory 83,423
Other Current Assets 295,648
Total Current Assets  (as reported)3,643,701
Total Current Assets  (calculated)3,643,701
+/-0
Long-term Assets
Property Plant Equipment 827,544
Goodwill 155,593
Long Term Investments 13,313
Intangible Assets 126,419
Long-term Assets Other 402,504
Long-term Assets  (as reported)2,177,653
Long-term Assets  (calculated)1,525,373
+/- 652,280

Liabilities & Shareholders' Equity

Total Current Liabilities1,278,619
Long-term Liabilities371,832
Total Stockholder Equity4,170,903
Total Current Liabilities
Accounts payable 241,094
Other Current Liabilities 119,722
Total Current Liabilities  (as reported)1,278,619
Total Current Liabilities  (calculated)360,816
+/- 917,803
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt42,408
Long-term Liabilities Other 340,072
Long-term Liabilities  (as reported)371,832
Long-term Liabilities  (calculated)382,480
+/- 10,648
Total Stockholder Equity
Total Stockholder Equity (as reported)4,170,903
Total Stockholder Equity (calculated)0
+/- 4,170,903
Other
Capital Stock194
Common Stock Shares Outstanding 194,123
Net Invested Capital 4,170,903
Net Working Capital 2,365,082
Property Plant and Equipment Gross 1,173,915



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
1,638,597
1,607,347
1,639,443
2,374,301
2,302,582
2,306,012
2,397,157
2,519,947
2,645,762
2,754,161
2,947,633
3,214,818
3,426,750
2,752,422
3,212,321
3,307,430
3,560,918
3,661,436
3,904,623
4,198,831
4,933,352
5,054,221
5,319,035
5,510,214
5,840,984
5,797,623
6,208,259
6,388,239
6,782,107
7,135,605
4,661,803
5,012,434
5,444,322
5,749,365
5,821,354
5,821,3545,749,3655,444,3225,012,4344,661,8037,135,6056,782,1076,388,2396,208,2595,797,6235,840,9845,510,2145,319,0355,054,2214,933,3524,198,8313,904,6233,661,4363,560,9183,307,4303,212,3212,752,4223,426,7503,214,8182,947,6332,754,1612,645,7622,519,9472,397,1572,306,0122,302,5822,374,3011,639,4431,607,3471,638,597
   > Total Current Assets 
994,178
819,175
844,803
1,541,322
1,504,854
1,469,555
1,598,084
1,700,359
1,832,254
1,904,500
2,058,625
2,319,595
2,481,488
1,716,169
2,077,625
2,159,425
2,359,894
2,449,969
2,620,060
2,923,797
3,118,674
3,288,091
3,625,845
3,821,111
4,092,850
3,971,633
4,264,433
4,402,665
4,645,402
4,849,091
2,567,085
2,808,708
3,239,030
3,507,421
3,643,701
3,643,7013,507,4213,239,0302,808,7082,567,0854,849,0914,645,4024,402,6654,264,4333,971,6334,092,8503,821,1113,625,8453,288,0913,118,6742,923,7972,620,0602,449,9692,359,8942,159,4252,077,6251,716,1692,481,4882,319,5952,058,6251,904,5001,832,2541,700,3591,598,0841,469,5551,504,8541,541,322844,803819,175994,178
       Cash And Cash Equivalents 
652,359
361,823
451,754
1,128,046
899,509
894,427
928,517
1,112,179
1,163,980
1,299,704
1,416,224
1,702,023
1,832,684
1,043,241
1,326,730
1,497,775
1,513,008
1,669,968
1,797,582
1,999,021
2,057,440
2,256,759
2,435,381
2,690,622
2,951,422
2,821,051
3,131,123
3,227,230
3,213,376
3,346,204
987,293
1,304,109
1,687,829
1,941,722
1,954,969
1,954,9691,941,7221,687,8291,304,109987,2933,346,2043,213,3763,227,2303,131,1232,821,0512,951,4222,690,6222,435,3812,256,7592,057,4401,999,0211,797,5821,669,9681,513,0081,497,7751,326,7301,043,2411,832,6841,702,0231,416,2241,299,7041,163,9801,112,179928,517894,427899,5091,128,046451,754361,823652,359
       Short-term Investments 
156,203
150,132
156,852
153,343
270,136
276,632
269,865
263,134
274,343
281,320
279,631
284,195
284,870
259,351
262,756
237,025
288,369
292,425
283,385
285,054
290,752
287,401
287,044
286,500
287,543
291,661
292,243
289,223
442,667
504,484
532,082
470,579
470,263
466,936
466,769
466,769466,936470,263470,579532,082504,484442,667289,223292,243291,661287,543286,500287,044287,401290,752285,054283,385292,425288,369237,025262,756259,351284,870284,195279,631281,320274,343263,134269,865276,632270,136153,343156,852150,132156,203
       Net Receivables 
148,758
244,975
169,516
198,345
266,299
220,190
316,310
247,736
307,598
244,081
302,680
276,116
308,809
351,522
420,250
356,182
481,994
397,357
438,170
516,689
616,300
562,344
682,968
618,188
644,879
623,788
637,994
657,263
743,557
745,526
739,050
758,450
853,154
823,134
842,892
842,892823,134853,154758,450739,050745,526743,557657,263637,994623,788644,879618,188682,968562,344616,300516,689438,170397,357481,994356,182420,250351,522308,809276,116302,680244,081307,598247,736316,310220,190266,299198,345169,516244,975148,758
       Inventory 
4,106
3,961
2,930
3,261
6,482
4,632
5,869
5,993
6,967
7,129
6,527
7,365
11,400
13,977
16,335
17,012
16,425
16,700
16,675
21,303
27,904
35,457
54,502
45,869
41,995
40,876
35,937
57,200
62,972
63,642
100,704
70,442
58,872
63,975
83,423
83,42363,97558,87270,442100,70463,64262,97257,20035,93740,87641,99545,86954,50235,45727,90421,30316,67516,70016,42517,01216,33513,97711,4007,3656,5277,1296,9675,9935,8694,6326,4823,2612,9303,9614,106
       Other Current Assets 
32,752
58,284
63,751
58,327
62,428
73,674
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
179,932
194,144
216,694
167,136
171,749
182,830
189,235
207,956
205,128
168,912
211,654
295,648
295,648211,654168,912205,128207,956189,235182,830171,749167,136216,694194,144179,9320000000000000000073,67462,42858,32763,75158,28432,752
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
849,661
889,008
895,223
945,262
1,036,253
1,134,696
1,148,005
1,201,024
1,211,467
1,284,563
1,275,034
1,814,678
1,766,130
1,628,908
1,689,103
1,642,037
1,686,865
1,943,826
1,985,574
2,136,705
2,286,514
2,094,718
2,203,726
2,205,292
2,241,944
2,177,653
2,177,6532,241,9442,205,2922,203,7262,094,7182,286,5142,136,7051,985,5741,943,8261,686,8651,642,0371,689,1031,628,9081,766,1301,814,6781,275,0341,284,5631,211,4671,201,0241,148,0051,134,6961,036,253945,262895,223889,008849,661000000000
       Property Plant Equipment 
182,872
207,759
218,878
246,825
259,763
264,610
267,586
300,767
319,751
338,331
369,470
376,940
406,625
438,656
481,910
527,458
588,076
622,657
689,043
713,851
751,468
0
748,677
742,412
765,608
767,550
774,983
757,926
777,048
745,532
787,544
798,174
794,214
795,251
827,544
827,544795,251794,214798,174787,544745,532777,048757,926774,983767,550765,608742,412748,6770751,468713,851689,043622,657588,076527,458481,910438,656406,625376,940369,470338,331319,751300,767267,586264,610259,763246,825218,878207,759182,872
       Goodwill 
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593
155,593155,593155,593155,593155,593155,593155,593155,593155,593155,593155,593155,593155,593155,593155,593155,593155,593155,593155,593155,593155,593155,593155,593155,593155,593155,593155,593155,593155,593155,593155,593155,593155,593155,593155,593
       Long Term Investments 
31,987
158,322
144,425
169,020
134,356
165,972
131,330
121,381
99,199
120,188
115,563
117,902
133,657
180,993
248,731
222,810
222,301
202,174
220,691
192,096
221,266
174,681
149,784
149,124
133,676
128,313
170,316
153,663
187,716
287,663
29,668
27,566
18,814
17,463
13,313
13,31317,46318,81427,56629,668287,663187,716153,663170,316128,313133,676149,124149,784174,681221,266192,096220,691202,174222,301222,810248,731180,993133,657117,902115,563120,18899,199121,381131,330165,972134,356169,020144,425158,32231,987
       Intangible Assets 
258,437
253,053
259,669
242,285
236,901
231,517
226,132
220,748
215,364
209,980
204,596
199,212
193,828
188,444
183,060
177,675
172,291
166,907
161,523
156,139
150,755
145,371
139,987
134,603
129,219
140,658
134,954
129,249
123,545
117,841
113,536
119,994
113,803
107,611
126,419
126,419107,611113,803119,994113,536117,841123,545129,249134,954140,658129,219134,603139,987145,371150,755156,139161,523166,907172,291177,675183,060188,444193,828199,212204,596209,980215,364220,748226,132231,517236,901242,285259,669253,053258,437
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
25,569
43,786
45,576
55,559
72,567
65,402
64,469
62,763
64,136
57,713
57,355
68,058
68,507
64,282
80,531
106,097
139,125
175,473
224,758
260,917
313,319
278,816
340,089
360,797
397,127
402,504
402,504397,127360,797340,089278,816313,319260,917224,758175,473139,125106,09780,53164,28268,50768,05857,35557,71364,13662,76364,46965,40272,56755,55945,57643,78625,569000000000
> Total Liabilities 
1,219,130
641,413
612,608
616,551
671,953
677,968
664,234
717,048
719,795
668,594
700,442
792,291
828,344
814,701
867,717
916,597
949,650
933,592
968,762
1,050,174
1,163,348
1,191,149
1,233,974
1,283,563
1,470,865
1,335,055
1,467,567
1,456,792
1,592,270
1,741,334
1,664,744
1,841,214
1,996,694
2,081,802
1,650,451
1,650,4512,081,8021,996,6941,841,2141,664,7441,741,3341,592,2701,456,7921,467,5671,335,0551,470,8651,283,5631,233,9741,191,1491,163,3481,050,174968,762933,592949,650916,597867,717814,701828,344792,291700,442668,594719,795717,048664,234677,968671,953616,551612,608641,4131,219,130
   > Total Current Liabilities 
273,501
304,716
293,161
319,935
375,396
381,072
368,239
422,489
425,277
364,515
367,105
461,683
513,340
503,412
556,513
606,202
631,195
623,881
660,324
742,712
854,308
886,163
926,674
1,006,596
1,157,077
1,006,111
1,118,773
1,124,680
1,240,379
1,396,453
1,337,055
1,501,650
1,641,847
1,720,290
1,278,619
1,278,6191,720,2901,641,8471,501,6501,337,0551,396,4531,240,3791,124,6801,118,7731,006,1111,157,0771,006,596926,674886,163854,308742,712660,324623,881631,195606,202556,513503,412513,340461,683367,105364,515425,277422,489368,239381,072375,396319,935293,161304,716273,501
       Short-term Debt 
0
0
23,428
23,711
7,393
7,460
7,554
7,648
0
10,245
0
0
18,300
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000018,3000010,24507,6487,5547,4607,39323,71123,42800
       Short Long Term Debt 
0
0
23,428
23,711
7,393
7,460
7,554
7,648
0
10,245
0
0
18,300
18,524
18,588
11,900
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000011,90018,58818,52418,3000010,24507,6487,5547,4607,39323,71123,42800
       Accounts payable 
253,962
283,188
69,093
69,933
67,671
74,115
75,559
95,478
103,827
70,363
66,184
95,376
83,647
60,937
90,909
122,512
98,767
85,058
122,100
114,509
172,110
152,547
194,770
163,175
277,546
55,633
155,538
139,411
109,601
164,238
148,174
178,710
197,465
195,537
241,094
241,094195,537197,465178,710148,174164,238109,601139,411155,53855,633277,546163,175194,770152,547172,110114,509122,10085,05898,767122,51290,90960,93783,64795,37666,18470,363103,82795,47875,55974,11567,67169,93369,093283,188253,962
       Other Current Liabilities 
19,539
21,528
22,779
24,330
33,448
28,175
35,801
91,965
74,085
90,231
86,174
93,322
88,796
109,132
124,286
101,442
109,018
137,850
129,745
136,764
109,858
127,930
103,263
107,176
112,078
170,150
123,781
127,419
111,747
102,505
94,721
96,874
98,103
116,241
119,722
119,722116,24198,10396,87494,721102,505111,747127,419123,781170,150112,078107,176103,263127,930109,858136,764129,745137,850109,018101,442124,286109,13288,79693,32286,17490,23174,08591,96535,80128,17533,44824,33022,77921,52819,539
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
304,079
333,337
330,608
315,004
311,289
311,204
310,395
318,455
309,711
308,438
307,462
309,040
304,986
271,193
276,967
254,262
250,848
348,794
332,112
351,891
344,881
327,689
339,564
354,847
361,512
371,832
371,832361,512354,847339,564327,689344,881351,891332,112348,794250,848254,262276,967271,193304,986309,040307,462308,438309,711318,455310,395311,204311,289315,004330,608333,337304,079000000000
       Capital Lease Obligations Min Short Term Debt
0
0
-23,428
-23,711
-7,393
-7,460
-7,554
-7,648
0
-10,245
32,434
42,867
23,625
41,890
43,165
45,539
47,531
46,130
45,241
43,625
44,821
44,085
34,193
42,080
33,262
32,848
39,741
38,104
38,287
37,395
37,548
36,507
43,544
43,119
42,408
42,40843,11943,54436,50737,54837,39538,28738,10439,74132,84833,26242,08034,19344,08544,82143,62545,24146,13047,53145,53943,16541,89023,62542,86732,434-10,2450-7,648-7,554-7,460-7,393-23,711-23,42800
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
286,432
283,832
280,796
283,086
279,330
279,287
277,547
285,882
277,557
276,600
276,086
277,408
273,601
237,000
246,491
221,000
218,000
319,303
303,253
322,729
315,947
298,944
311,341
321,305
328,869
340,072
340,072328,869321,305311,341298,944315,947322,729303,253319,303218,000221,000246,491237,000273,601277,408276,086276,600277,557285,882277,547279,287279,330283,086280,796283,832286,432000000000
> Total Stockholder Equity
419,467
965,934
1,026,835
1,757,750
1,630,629
1,628,044
1,732,923
1,802,899
1,925,967
2,085,567
2,247,191
2,422,527
2,598,406
1,937,721
2,344,604
2,390,833
2,611,268
2,727,844
2,935,861
3,148,657
3,770,004
3,863,072
4,085,061
4,226,651
4,370,119
4,462,568
4,740,692
4,931,447
5,189,837
5,394,271
2,997,059
3,171,220
3,447,628
3,667,563
4,170,903
4,170,9033,667,5633,447,6283,171,2202,997,0595,394,2715,189,8374,931,4474,740,6924,462,5684,370,1194,226,6514,085,0613,863,0723,770,0043,148,6572,935,8612,727,8442,611,2682,390,8332,344,6041,937,7212,598,4062,422,5272,247,1912,085,5671,925,9671,802,8991,732,9231,628,0441,630,6291,757,7501,026,835965,934419,467
   Common Stock
189
205
205
211
211
212
212
213
213
214
215
215
216
217
218
219
219
220
220
221
221
221
222
222
223
223
0
0
0
0
0
0
0
0
0
000000000223223222222221221221220220219219218217216215215214213213212212211211205205189
   Retained Earnings Total Equity00000000000000000000000000000000000
   Accumulated Other Comprehensive Income 00000000000000000000000000000000000
   Capital Surplus 00000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000
   Other Stockholders Equity 
-2,886
5,377
10,968
12,512
-7,010
-10,122
-9,809
-9,522
-10,165
-9,247
-8,965
-8,614
-15,542
-13,107
-12,423
-9,748
-15,360
-20,358
-18,273
-18,646
-19,454
-23,047
-25,696
-29,062
15,069
20,942
0
0
0
0
0
0
0
0
0
00000000020,94215,069-29,062-25,696-23,047-19,454-18,646-18,273-20,358-15,360-9,748-12,423-13,107-15,542-8,614-8,965-9,247-10,165-9,522-9,809-10,122-7,01012,51210,9685,377-2,886



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue4,241,217
Cost of Revenue-312,100
Gross Profit3,929,1173,929,117
 
Operating Income (+$)
Gross Profit3,929,117
Operating Expense-4,139,923
Operating Income101,294-210,806
 
Operating Expense (+$)
Research Development2,606,848
Selling General Administrative1,222,000
Selling And Marketing Expenses-
Operating Expense4,139,9233,828,848
 
Net Interest Income (+$)
Interest Income128,710
Interest Expense-2,280
Other Finance Cost-0
Net Interest Income126,430
 
Pretax Income (+$)
Operating Income101,294
Net Interest Income126,430
Other Non-Operating Income Expenses-
Income Before Tax (EBT)316,63012,463
EBIT - interestExpense = -2,280
32,615
34,895
Interest Expense2,280
Earnings Before Interest and Taxes (EBIT)-318,910
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax316,630
Tax Provision-284,015
Net Income From Continuing Ops32,61532,615
Net Income32,615
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net88,831-126,430
 

Technical Analysis of Incyte
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Incyte. The general trend of Incyte is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Incyte's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Incyte Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Incyte Corporation.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 73.70 < 75.00 < 78.52.

The bearish price targets are: 69.58 > 68.24 > 61.30.

Know someone who trades $ICY? Share this with them.πŸ‘‡

Incyte Corporation Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Incyte Corporation. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Incyte Corporation Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Incyte Corporation. The current macd is 0.3771625.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Incyte price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Incyte. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Incyte price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Incyte Corporation Daily Moving Average Convergence/Divergence (MACD) ChartIncyte Corporation Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Incyte Corporation. The current adx is 15.41.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Incyte shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Incyte Corporation Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Incyte Corporation. The current sar is 69.66.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Incyte Corporation Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Incyte Corporation. The current rsi is 56.65. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Incyte Corporation Daily Relative Strength Index (RSI) ChartIncyte Corporation Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Incyte Corporation. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 5/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Incyte price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Incyte Corporation Daily Stochastic Oscillator ChartIncyte Corporation Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Incyte Corporation. The current cci is 82.15.

Incyte Corporation Daily Commodity Channel Index (CCI) ChartIncyte Corporation Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Incyte Corporation. The current cmo is 17.82.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Incyte Corporation Daily Chande Momentum Oscillator (CMO) ChartIncyte Corporation Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Incyte Corporation. The current willr is -7.76699029.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Incyte Corporation Daily Williams %R ChartIncyte Corporation Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Incyte Corporation.

Incyte Corporation Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Incyte Corporation. The current atr is 1.01793938.

Incyte Corporation Daily Average True Range (ATR) ChartIncyte Corporation Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Incyte Corporation. The current obv is -3,934.

Incyte Corporation Daily On-Balance Volume (OBV) ChartIncyte Corporation Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Incyte Corporation. The current mfi is 53.78.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Incyte Corporation Daily Money Flow Index (MFI) ChartIncyte Corporation Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Incyte Corporation.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-05-23 00:00:00MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-28 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-30 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-03 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-04 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-06 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-09 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-10 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-11 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-12 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-16 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-17 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-18 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-19 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-20 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-23 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-24 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-25 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-26 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-27 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-30 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-01 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-02 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-03 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-04 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-08 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-10 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-11 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-14 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-15 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-16 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-17 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-21 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-22 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-23 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-24 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-28 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-29 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-30 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-31 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-01 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-05 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-07 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-11 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-13 00:00:00CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-14 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-15 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-08-18 00:00:00MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-08-19 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-20 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-08-21 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-25 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-26 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-08-27 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-08-28 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-29 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-09-02 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-03 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-05 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-08 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-09 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-11 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-12 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-15 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-09-16 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-09-17 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-18 00:00:00CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-22 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-09-23 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-25 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-26 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-29 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-02 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Incyte Corporation Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Incyte Corporation based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5056.652
Ma 20Greater thanMa 5072.063
Ma 50Greater thanMa 10070.959
Ma 100Greater thanMa 20064.718
OpenGreater thanClose73.380
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Incyte with someone you think should read this too:
  • Are you bullish or bearish on Incyte? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Incyte? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Incyte Corporation

I send you an email if I find something interesting about Incyte Corporation.


Comments

How you think about this?

Leave a comment

Stay informed about Incyte Corporation.

Receive notifications about Incyte Corporation in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.